Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

By sjmartinez • October 22, 2022

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. PMID: 34597472.

Tags: BladderCancer, blcsm, Hematology/Oncology, immune checkpoint, immunotherapy, inhibitors, Outcomes, Publications, urinary tract neoplasms, uroonc, urothelial carcinoma, utuc

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa[...]

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates

Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.